|
|
 |
|
Viewing report
|
|
|
|
China Hypertension Drug Market 2008
Draco Healthcare Consulting LLC, Feb 2009, Pages: 107
Epidemiology data indicate that there are about 200 million hypertension patients in China. Every year there are 2 million newly added patients with stroke, 500,000 newly added patients with myocardial infarction and 3 million patients died of cardiovascular and cerebrovascular diseases. Annual costs for the treatment of cardiovascular and cerebrovascular diseases in China are about RMB 130 billion (USD 18 billion), among which RMB 36.6 billions (USD 5.14 billion) are for hypertension treatment.
The Chinese theoretic market demand for hypertension drugs is USD 6.7 billion and the actual hypertension drug sales in China in 2007 are about USD 1.2 billion. Sales of hypertension drugs in the Chinese hospital market have been on a steady rise since 2003. Sales growths for hypertension drugs in China are 19.67%, 14.22%, 3% and 10.75% in 2004, 2005, 2006 and 2007 respectively.
This report has systemically analyzed the Chinese hypertension drug market. All calculations of drug utilization in China are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions (20-60% of hospital beds coverage).
Market shares from all major players including multinational and Chinese pharmaceutical companies and their major hypertension products are analyzed systemically based on data from significant number of Chinese hospitals. The comprehensive hospital utilization data of major hypertension drugs will present you a clear picture of the competition landscape of Chinese hypertensions drug market and the market potential for your company's product(s) that already marketed in China or if you are planning to bring your drugs to the China market.
This China Hypertension Drug Market Report has been a Must-have reference for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies.
Compared to expensive customized drug utilization reports in China, this multi-client report provides tremendous value with significant savings and great cost/benefit to pharmaceutical companies and interested parties.
Products Mentioned:
- Amlodipine
- Nifedipine
- Valsartan
- Felodipine
- Losartan Potassium
- Irbesartan
- Benazepril
- Nimodipine
- Levamlodipine
- Fosinopril
- Bisoprolol
- Metoprolol
- Telmisartan
- Perindopril
- Urapidil
- Carvedilol
- Irbesartan Hydrochlorothiazide
- Doxazosin
- Diltiazem
- Torsemide
Customers who bought this item also bought
Chinese Markets for Hypertension Drugs
Hypertension: Treatments and Prescribing Practices - A Global Survey
Strategic Analysis of the Kenyan Hypertension Markets
Handbook of Hypertension
Disease and Therapy Review: Hypertension
Medicines for Hypertension Prevention and Cure in China
China Executive Summary of the Chinese Hospital Drug Utilization Volume 2nd Edition 2009
Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaos
Cardiovascular Generic Drugs: Prospects and Opportunities to 2012
Renin Inhibitors: A Novel Approach to Hypertension
Drugs of Tomorrow 2001: Hypertension - The Mounting Pressures Facing New Compounds
Hypertension - Multiple Layers of Therapy Cover all Eventualities
|
|
|
|
